Biologics and Antibody Therapy Markets Projected to Reach Hundreds of Billions by 2033

Multiple market reports project robust growth in the global biologics and antibody therapy markets, driven by rising demand for monoclonal antibodies, the expansion of biosimilars, and advances in targeted therapies. The antibody therapy market is expected to grow from US$ 231.6 billion in 2023 to US$ 669.1 billion by 2033, at a compound annual growth rate (CAGR) of 11.2%. Monoclonal antibodies dominated the type segment in 2023, accounting for more than 69.1% of the total antibody therapy market share.

The broader biologics market, which includes monoclonal antibodies, gene therapies, recombinant proteins, and vaccines, was valued at USD 377.6 billion in 2024. It is estimated to reach USD 769.7 billion by 2033, exhibiting a CAGR of 7.38% during 2025–2033. In the biologics market, monoclonal antibodies dominate by product with a 66.7% share, while oncology holds the largest disease segment at 28.7%.

Within the autoimmune neurological disorders market, which focuses on conditions where the immune system attacks the nervous system, the global market size accounted for USD 8.50 billion in 2025. It is predicted to increase from USD 9.17 billion in 2026 to approximately USD 17.79 billion by 2035, expanding at a CAGR of 7.90% from 2026 to 2035. The monoclonal antibodies segment in this market held a major share of 28% in 2025 and is expected to sustain its dominance with a CAGR of 10.5%.

North America holds a leading position across these markets. In the antibody therapy market, North America represented 38.9% of the global share in 2023, with a market valuation of US$ 90.1 billion. In the biologics market, North America holds a share of over 44.8% in 2024. In the autoimmune neurological disorders market, North America dominated with a share of 40% in 2025. The Asia-Pacific region is noted as the fastest growing, with an expected CAGR of 11.5% in the autoimmune neurological disorders market.

The expansion of biosimilars is a key driver. In the biologics market, biosimilar manufacturers are launching cost-effective alternatives as blockbuster biologics come off patent. For example, Biocon Biologics secured US market access for its biosimilar YESINTEK, covering over 100 million lives—roughly 70–80% of the commercial market—in a single formulary push. India's government healthcare spending reached approximately USD 51 billion, with public investment targeted to reach 2.5% of GDP, directly funding biosimilar accessibility programs.

Emerging trends across the sectors include the rise of targeted biologics and biosimilars, the expansion of CAR-T cell therapy, and the increasing use of artificial intelligence (AI) for diagnostics and drug discovery. AI algorithms are being used to analyze complex medical scans for early detection, screen potential molecular interactions, and repurpose existing drugs. Regulatory harmonization and accelerated approval pathways are also speeding up global market entry for novel biologics and antibody therapies.